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Introduction {#cam41243-sec-0001}
============

Lung cancer is one of the most common malignancies and the leading cause of worldwide cancer mortality [1](#cam41243-bib-0001){ref-type="ref"}. Limitations (such as drug resistance) have emerged in traditional strategies, including chemotherapy and molecular‐targeted therapy. Since the approval of pembrolizumab as a first‐line therapy in non‐small cell lung cancer (NSCLC) therapy, increased attention has been paid to the study of immune checkpoints [2](#cam41243-bib-0002){ref-type="ref"}. Currently, the markers of interest are the CD8^+^ tumor infiltrating lymphocytes (TILs) density and the expression levels of tumor programmed cell death ligand‐1 (PD‐L1) [3](#cam41243-bib-0003){ref-type="ref"}.

Programmed death receptor‐1 (PD‐1) is a protein receptor of the CD28 family expressed on the surface of T, B, and natural killer (NK) cells that regulates their activation and proliferation. Its ligand, PD‐L1, is frequently overexpressed in many kinds of human malignancies. The binding of PD‐L1 to PD‐1 induces apoptosis or exhaustion in activated T cells and limits the effector function of T cells in peripheral tissues during inflammatory responses [4](#cam41243-bib-0004){ref-type="ref"}. Blockade of PD‐1/PD‐L1 pathway has been shown to enhance the antitumor effector functions in the tumor microenvironment including T‐cells activity [5](#cam41243-bib-0005){ref-type="ref"}, [6](#cam41243-bib-0006){ref-type="ref"}. Anti‐PD‐1/PD‐L1 antibodies, such as nivolumab, pembrolizumab, and atezolizumab have demonstrated promising and amazing efficacy against various tumors in several clinical trials, especially those involving NSCLC [7](#cam41243-bib-0007){ref-type="ref"}, [8](#cam41243-bib-0008){ref-type="ref"}, [9](#cam41243-bib-0009){ref-type="ref"}, [10](#cam41243-bib-0010){ref-type="ref"}. Preliminary studies of NSCLC patients indicate that clinical benefits to immune checkpoint inhibitors are associated with elevated PD‐L1 expression levels on tumor cells and increased TILs numbers [9](#cam41243-bib-0009){ref-type="ref"}, [11](#cam41243-bib-0011){ref-type="ref"}. Moreover, Teng and colleagues proposed that four different types of tumor microenvironment exist based on the presence or absence of TILs and PD‐L1 expression levels (type I: TILs^+^ and PD‐L1^+^; type II: TILs^−^ and PD‐L1^−^; type III: TILs^+^ and PD‐L1^−^; type IV: TILs^−^ and PD‐L1^+^) [12](#cam41243-bib-0012){ref-type="ref"}. Different types of tumor microenvironment show distinct responses to PD‐1/PD‐L1 antibodies. Type I tumors could gain the greatest benefit from PD‐1/PD‐L1 antibodies treatment [12](#cam41243-bib-0012){ref-type="ref"}. This suggested that both PD‐L1 expression and TILs density may play a critical role in tumor microenvironment and immune checkpoint therapy. However, the prognostic value of PD‐L1 expression and CD8^+^ TILs density in Chinese NSCLC patients remains unclear. To date, few studies focusing on this issue have been published, and the case number of those studies is small [13](#cam41243-bib-0013){ref-type="ref"}. Furthermore, those studies evaluated samples only obtained by tumor biopsies, which were too small for assessment of the location and orientation of CD8^+^ TILs. Their results concerning the correlation between PD‐L1 expression/CD8^+^ TILs and prognosis in NSCLC are inconsistent [14](#cam41243-bib-0014){ref-type="ref"}, [15](#cam41243-bib-0015){ref-type="ref"}, [16](#cam41243-bib-0016){ref-type="ref"}.

Hence, we performed this study that aimed to investigate the prevalence and prognostic value of PD‐L1 expression and CD8^+^ TILs density in Chinese patients with surgically resected NSCLC. We also analyzed the correlation between clinicopathological characteristics and PD‐L1 expression/CD8^+^ TILs density in NSCLC.

Methods {#cam41243-sec-0002}
=======

Study patients {#cam41243-sec-0003}
--------------

Patients who were diagnosed with NSCLC and underwent surgical resection at Yancheng Third People\'s Hospital and Shanghai Pulmonary Hospital from 2011 to 2015 were evaluated. Patients with missing baseline clinicopathological characteristics and follow‐up data were excluded. Of the remaining patients, those who had formalin‐fixed and paraffin‐embedded (FFPE) specimens representing primary lesions containing adequate tumor cells and T cells were enrolled in this study. Patients who were staged as p‐TxN1‐3Mx without FFPE specimens representing metastatic lymph nodes were excluded. Finally, 178 total eligible patients were included. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee and Institutional Review Board (IRB) of Yancheng Third People\'s Hospital and Shanghai Pulmonary Hospital. A written informed consent was obtained from each participant in order to use the clinical data for research.

Immunohistochemistry {#cam41243-sec-0004}
--------------------

Immunohistochemistry was performed according to the protocol recorded in our previous study [17](#cam41243-bib-0017){ref-type="ref"}. In this study, anti‐human PD‐L1 (\#13684, clone E1L3N, Cell Signaling Technology, Danvers, MA, diluted 1:200) and CD8 monoclonal antibodies (\#M7103, clone C8144B, DAKO, Glostrup, Denmark, diluted 1:200) were used as primary antibodies, and a peroxidase‐labeled secondary antibody (REAL EnVision Detection Reagent Peroxidase Rabbit/Mouse, DAKO, Glostrup, Denmark) was applied to visualize the antigen. PD‐L1 expression was defined as the percentage of tumor cells displaying membranous immunoreactivity, either in the central or marginal tumor region; and PD‐L1^−/+^ was determined by cut‐off value of 5%, which was based on several previous clinical trials of anti‐PD‐1/PD‐L1 drugs in NSCLC; [11](#cam41243-bib-0011){ref-type="ref"}, [18](#cam41243-bib-0018){ref-type="ref"}, [19](#cam41243-bib-0019){ref-type="ref"} among PD‐L1^+^ cases, we defined PD‐L1 strong positivity (PD‐L1^high^) as PD‐L1 \> 50% (Fig. [S1](#cam41243-sup-0001){ref-type="supplementary-material"}). Lymphocytes with cytoplasmic expression of CD8 infiltrating within tumor region, either in the central or marginal tumor region, were defined as CD8^+^ TILs (Fig. [S1](#cam41243-sup-0001){ref-type="supplementary-material"}). Based on the percentage of CD8^+^ TILs presented within tumor region, we stipulated CD8^low/high^ TILs with cut‐off value of 5%, which was determined in a manner similar to that of a previous publication [13](#cam41243-bib-0013){ref-type="ref"}. Moreover, breast cancer cell line MDA‐MB‐231 and placenta tissues were used as the positive controls for PD‐L1 IHC‐staining, and breast cancer cell line MCF‐7 was used as the negative control for PD‐L1 IHC‐staining (Fig. [S2](#cam41243-sup-0002){ref-type="supplementary-material"}). All IHC analyses were evaluated by two experienced pathologists by means of manual quantification through their naked eyes, and the mean value of the determinations was used for further analyses. The Pearson\'s correlation coefficient between the two pathologists for CD8^+^ TILs as a continuous variable was as follows: *r *=* *0.79; *P *\<* *0.001. Neither pathologists were aware of the identity of the specimens.

ODM analyses {#cam41243-sec-0005}
------------

All oncogenic driver mutation (ODM) analyses were performed at Thoracic Cancer Institute, Tongji University School of Medicine (Shanghai, China). *EGFR*,*KRAS*,*ALK*,*ROS1*,*HER2*, and *RET* status were detected as described in our previous studies [20](#cam41243-bib-0020){ref-type="ref"}, [21](#cam41243-bib-0021){ref-type="ref"}, [22](#cam41243-bib-0022){ref-type="ref"}, [23](#cam41243-bib-0023){ref-type="ref"}. All the ODM analyses were identified by the commercially available AmoyDx^®^ Gene Mutation Detection Kits (AmoyDx Co. Ltd., Xiamen, China). To express ODM concisely, ODM^+^ refers to any one or more oncogenic driver mutations and ODM^−^ refers to pan‐negative for the six above‐mentioned oncogenic diver mutations.

Statistical analyses {#cam41243-sec-0006}
--------------------

Correlations between PD‐L1 expression/CD8^+^ TILs density and patients\' clinicopathological characteristics were performed with Chi‐square test for categorical variables and ANOVA and Tukey\'s multiple comparison tests for continuous variables. The Kaplan--Meier method was used for survival analyses, and the significance of differences between groups was evaluated by the log‐rank test. The Cox proportional hazards model was used for univariate and multivariate analyses to calculate the hazard ratios (HR) and 95% confidence intervals (95% CI). Overall survival (OS) was calculated from the date of diagnosis to death from any cause or was censored at the last follow‐up date. *P* values were considered statistically significant if \<0.05 (two‐sided). All statistical analyses were performed by SPSS for Windows (version 17.0; IBM Corporation, Armonk, NY, USA).

Results {#cam41243-sec-0007}
=======

Clinicopathological characteristics {#cam41243-sec-0008}
-----------------------------------

A total of 178 patients were included. The median age at diagnosis was 62 years (range: 24--77 years). One‐hundred thirteen (63.5%) patients were male, and 103 (57.9%) patients had a history of smoking. The majority of histological types was adenocarcinoma (ADC, 137/178), including five lepidic, 18 papillary, 81 acinar, 29 solid, three enteric and one minimally invasive ADC (IMA), which was followed by 41 squamous cell carcinomas (SqCCs). Of them, 85 (47.8%), 47 (26.4%), 39 (21.9%; IIIA, 37; IIIB, 2), and seven (3.9%) patients had stages I--IV diseases at the time of diagnosis. With respect to ODM status, *EGFR*,*KRAS*,*HER2*,*RET*,*ALK*, and *ROS1* alterations were detected in 73, 16, five, four, three, and three cases, respectively (co‐alterations were detected in six cases). We found that PD‐L1^high^ was more likely to be detected in patients with SqCC (*P *=* *0.001), *EGFR* wild type (*EGFR* ^−^) (*P *=* *0.045), and ODM^−^ (*P *=* *0.046) (Table [1](#cam41243-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline clinicopathological characteristics and molecular alterations of included patients (n = 178)

                   Total   PD‐L1 \> 5%   PD‐L1 ≤ 5%   *P*         PD‐L1 \> 50%   PD‐L1 ≤ 50%   *P*         CD8 high   CD8 low   *P*
  ---------------- ------- ------------- ------------ ----------- -------------- ------------- ----------- ---------- --------- -----------
  Age                                                                                                                           
  \<65             110     43            67           0.782       26             84            0.836       48         62        0.477
  ≥65              68      28            40                       17             51                        26         42        
  Sex                                                                                                                           
  Male             113     54            59           **0.005**   32             81            0.087       48         65        0.747
  Female           65      17            48                       11             54                        26         39        
  Smoking                                                                                                                       
  Never            75      20            55           **0.002**   14             61            0.144       24         51        **0.027**
  Current/former   103     51            52                       29             74                        50         53        
  Histology                                                                                                                     
  ADC              137     46            91           **0.002**   24             109           **0.001**   51         86        **0.031**
  Solid            29      18            11                       12             17                        14         15        
  Lepidic          10      5             5                        5              5                         2          3         
  Papillary        18      5             13                       3              15                        9          9         
  Acinar           77      21            56                       9              68                        22         55        
  Others           8       2             6                        1              7                         4          4         
  SqCC             41      25            16                       19             26                        23         18        
  p‐Stage                                                                                                                       
  I                85      33            52           0.782       21             64            0.870       43         42        **0.020**
  II--IV           93      38            55                       22             71                        31         62        
  I--II            132     51            81           0.564       34             98            0.398       60         72        0.075
  III--IV          46      20            26                       9              37                        14         32        
  *EGFR*                                                                                                                        
  Wild type        105     52            53           **0.002**   31             74            **0.045**   52         53        **0.010**
  Mutant type      73      19            54                       12             61                        22         51        
  *KRAS*                                                                                                                        
  Wild type        162     61            101          0.053       38             124           0.487       64         98        0.075
  Mutant type      16      10            6                        5              11                        10         6         
  ODM                                                                                                                           
  Wild type        80      40            40           **0.013**   25             55            **0.046**   38         42        0.147
  Mutant type      98      31            67                       18             80                        36         62        

PD‐L1, programmed cell death ligand‐1; ADC, adenocarcinoma; SqCC, squamous cell carcinoma; *EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene*; ODM, oncogenic driver mutations.
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The correlation between PD‐L1 Expression/CD8^+^ TILs density and OS among the patients {#cam41243-sec-0009}
--------------------------------------------------------------------------------------

PD‐L1^+^ was detected in 71 (39.9%) patients, and it was significantly associated with male gender (*P *=* *0.005), current/former smokers (*P *=* *0.002), SqCC (*P *=* *0.002), and *EGFR* ^−^ (*P *=* *0.002), but not with age (*P *=* *0.782), p‐stage (*P *=* *0.782), or *KRAS* mutation status (*P *=* *0.053). We restricted our analyses to CD8^+^ TILs due to tissue availability, which is generally thought to be the population mainly benefitting from treatment with PD‐1/PD‐L1 antibodies [24](#cam41243-bib-0024){ref-type="ref"}. CD8^high^ TILs were detected in 74 (41.6%) cases and were significantly associated with smoking (*P *=* *0.027), SqCC (*P *=* *0.031), p‐stage I (*P *=* *0.020) and *EGFR* ^−^ (*P *=* *0.010). In addition, it was observed that CD8^high^ was associated with PD‐L1^+^/PD‐L1^high^, and CD8^low^ was associated with PD‐L1^−^ (*P *\<* *0.001) (Table [1](#cam41243-tbl-0001){ref-type="table-wrap"}).

Furthermore, we analyzed the correlation between PD‐L1 expression/CD8^+^ TILs density and OS. The median follow‐up time was 27 months (range, 6--55 months). Among the entire cohort, patients with CD8^high^ TILs had longer OS (*P *=* *0.012), but there was no statistical difference between PD‐L1^−/+^ and OS (*P *=* *0.987). In patients with ADC and solid ADC, we obtained similar results in which CD8^high^ TILs were associated with better OS (*P *=* *0.030 & 0.036, respectively), and PD‐L1^−/+^ showed no correlation with OS (*P *=* *0.119 & 0.142, respectively). Interestingly, in patients with non‐solid ADC and SqCC, PD‐L1^+^ was associated with more satisfactory OS than PD‐L1^−^ (*P *=* *0.022 & 0.033, respectively), however, CD8^+^ TILs density did not correlate with OS (*P *=* *0.116 & 0.464, respectively). When we sub‐grouped PD‐L1^low/high^ in PD‐L1^+^ cases for survival analyses, statistically significant difference was only achieved in patients with non‐solid ADC (*P *=* *0.037) (Fig. [1](#cam41243-fig-0001){ref-type="fig"}). The prognostic value of PD‐L1 expression and CD8^+^ TILs density in p‐stages I/II NSCLC patients was also investigated. In this cohort, no prognostic value of the two parameters was verified (*P *=* *0.680 & 0.204, respectively), not even both combined (*P *=* *0.082) (Fig. [2](#cam41243-fig-0002){ref-type="fig"}).

![**The correlation between the expression levels of PD‐L1 (on tumor cells) or CD8^+^ TILs density and OS among NSCLC patients**. CD8^high^ TILs was associated with better OS, but the expression levels of PD‐L1 showed no correlation with OS among NSCLC patients (A--C), patients with ADC (D--F), and solid ADC (G--I), respectively; in patients with SqCC (M--O), PD‐L1^+^ was associated with longer OS, but CD8^+^ TILs density showed no correlation with OS; on the contrary, in patients with non‐solid ADC (J--L), PD‐L1^--^ may suggest favorable OS, and patients with PD‐L1^low^ reached the longest OS, but CD8^+^ TILs density showed no correlation with OS.](CAM4-7-32-g001){#cam41243-fig-0001}

![**Survival analysis of p‐stage I/II NSCLC patients based on the expression levels of PD‐L1 (on tumor cells), CD8^+^ TILs density and the combination of PD‐L1 expression (5% cut‐off) and CD8^+^ TILs density (5% cut‐off).** As for p‐stage I/II NSCLC patients, the expression levels of either PD‐L1 or CD8 was not associated with OS, not even the combination of both.](CAM4-7-32-g002){#cam41243-fig-0002}

Among the whole cohort, univariate and multivariate analyses were performed. Multivariate analyses revealed that p‐stages II‐IV (vs. p‐stage I; HR = 2.105; 95% CI, 1.036--4.279; *P *=* *0.040) and CD8^high^ TILs (vs. CD8^low^ TILs; HR = 0.411; 95% CI, 0.177--0.954; *P *=* *0.038) were independent and significant predictive factors for OS in NSCLC instead of PD‐L1 expression (HR = 1.682; 95% CI, 0.833--3.397; *P *=* *0.147) (Table [2](#cam41243-tbl-0002){ref-type="table-wrap"}).

###### 

Univariate and multivariate analyses of clinicopathological factors associated with OS

                   Univariate   Multivariate                                      
  ---------------- ------------ -------------- ----------- ------- -------------- -----------
  Age                                                                             
  \<65             1            0.954--3.393   0.070       1.684   0.880--3.222   0.115
  ≥65              1.799                                                          
  Sex                                                                             
  Male             1            0.467--1.658   0.692                              
  Female           0.880                                                          
  Smoking                                                                         
  Never            1            0.863--3.076   0.132                              
  Current/former   1.630                                                          
  Histology                                                                       
  Solid            1            0.260--1.025   0.059       0.587   0.283--1.215   0.151
  Non‐solid        0.516                                                          
  p‐Stage                                                                         
  I                1            1.345--5.290   **0.005**   2.105   1.036--4.279   **0.040**
  II--IV           2.667                                                          
  PD‐L1                                                                           
  Negative         1            0.871--3.143   0.124       1.682   0.833--3.397   0.147
  Positive         1.655                                                          
  CD8                                                                             
  Low              1            0.199--0.943   **0.035**   0.411   0.177--0.954   **0.038**
  High             0.433                                                          
  *EGFR*                                                                          
  Wild type        1            0.509--1.791   0.886                              
  Mutant type      0.955                                                          
  *KRAS*                                                                          
  Wild type        1            0.267--2.129   0.593                              
  Mutant type      0.754                                                          
  ODM                                                                             
  Wild type        1            0.413--1.461   0.434                              
  Mutant type      0.777                                                          

OS, overall survival; HR, hazard ratio; CI, confidence interval; PD‐L1, programmed cell death ligand‐1; *EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene;* ODM, oncogenic driver mutations.

John Wiley & Sons, Ltd

The correlation between combination of PD‐L1 expression & CD8^+^ TILs density and OS among the patients {#cam41243-sec-0010}
-------------------------------------------------------------------------------------------------------

We divided the patients into four subgroups (PD‐L1^+^/CD8^high^, PD‐L1^+^/CD8^low^, PD‐L1^−^/CD8^high^, and PD‐L1^−^/CD8^low^). Statistical differences were achieved in patients with NSCLC, ADC and non‐solid ADC (*P *=* *0.025, 0.010 & 0.026, respectively), but not in patients with solid ADC and SqCC (*P *=* *0.156 & 0.087, respectively). Among the whole cohort, the longest OS was achieved in patients with PD‐L1^+^/CD8^high^, and the shortest was in PD‐L1^+^/CD8^low^ (median OS was not reached). In groups of ADC and non‐solid ADC, patients with PD‐L1^+^/CD8^low^ experienced the worst OS (median OS: 27.0 months & 29.0 months, respectively), and patients with PD‐L1^−^/CD8^high^ achieved the best OS (median OS was undefined in both groups) (Fig. [3](#cam41243-fig-0003){ref-type="fig"}).

![**Kaplan--Meier survival curves of patients with NSCLC (A), ADC (B), solid ADC (C), non‐solid ADC (D), and SqCC (E) sub‐grouped by the combination of PD‐L1 expression (5% cut‐off) and CD8^+^ TILs density (5% cut‐off).** Significant statistical differences were shown in patients with NSCLC, ADC and non‐solid ADC (*P *= 0.025, 0.010 & 0.026, respectively). In patients with ADC and non‐solid ADC, patients with PD‐L1^--^/CD8^high^ had the longest OS, and PD‐L1^+^/CD8^low^ had the shortest OS. However, among the whole NSCLC patients, patients with PD‐L1^+^/CD8^high^ had the longest OS, and PD‐L1^--^/CD8^low^ had the shortest OS. No statistical differences were shown in patients with solid ADC and SqCC.](CAM4-7-32-g003){#cam41243-fig-0003}

The Correlation between PD‐L1 expression/CD8^+^ TILs density and OS among the patients with diverse ODM status {#cam41243-sec-0011}
--------------------------------------------------------------------------------------------------------------

In patients with *EGFR* ^−^ or *KRAS* ^−^, CD8^high^ TILs were associated with better OS (*P *=* *0.047 & 0.039, respectively), but there was no statistically significant difference between PD‐L1 expression levels and OS. In patients with *EGFR* ^+^ and *KRAS* ^+^, PD‐L1 expression levels or CD8^+^ TILs density were not associated with OS. In patients with ODM^+^, it was observed that PD‐L1^−^ was associated with longer OS (*P *=* *0.047); in contrast, PD‐L1^+^ was associated with longer OS in patients with ODM^−^ (*P *=* *0.048), and there was no correlation between CD8^+^ TILs density and OS in both groups of patients (*P *=* *0.083 & 0.053, respectively). It is worth mentioning that whether statistically significant differences were reached or not, CD8^high^ TILs showed a tendency for better OS than did CD8^low^ TILs in each group of patients, and PD‐L1^+^/PD‐L1^−^ showed a tendency for longer OS than did PD‐L1^−^/PD‐L1^+^ in patients with ODM^−^/ODM^+^, respectively (Fig. [4](#cam41243-fig-0004){ref-type="fig"}). However, given the number of *KRAS* ^+^ tumors in the series is not quite large, large‐cohort studies are needed to further confirm the related conclusions.

![**The correlation between the expression levels of PD‐L1 (on tumor cells) or CD8^+^ TILs density and OS among NSCLC patients with diverse ODM status.** In NSCLC patients with *EGFR* ^+^ (A--C) and *KRAS* ^+^ (G--I), no statistical differences were shown. In NSCLC patients with *EGFR* ^--^ (D--F) and *KRAS* ^--^ (J--L), patients with CD8^high^ had longer OS than those with CD8^low^ (*P *= 0.047 & 0.039, respectively). In patients with ODM^+^ (M--O) and ODM^--^ (P--R), it showed no correlation between CD8^+^ TILs density and OS; PD‐L1 expression (5% cut‐off) was associated with OS in both groups of patients: ODM^+^ patients with PD‐L1^--^ had longer OS (*P *= 0.047), meanwhile, ODM^--^ patients with PD‐L1^+^ had longer OS (*P *= 0.048).](CAM4-7-32-g004){#cam41243-fig-0004}

Expression consistency of PD‐L1/CD8^+^ TILs between primary lesions and corresponding lymph nodes in NSCLC patients and analyses of OS {#cam41243-sec-0012}
--------------------------------------------------------------------------------------------------------------------------------------

In the whole cohort, 58 patients had metastatic lymph nodes, so we assessed the expression consistency of PD‐L1 protein on tumor cells using the 58 pairs of samples. Consistent and inconsistent PD‐L1 expression levels between primary lesions and metastatic lymph nodes were found in 35 and 23 patients, respectively. After performing survival analyses, statistically significant differences between CD8^high^ TILs and longer OS in the 58 patients and patients with consistent PD‐L1 expression (*P *=* *0.017 & 0.049, respectively) were noted, but no correlation between CD8^+^ TILs density and OS in patients with inconsistent PD‐L1 expression (*P *=* *0.162). Due to tissue availability, we assessed the expression consistency of CD8^+^ TILs in 160 patients. Consistent expression was detected in 87 patients. Survival analyses indicated that CD8^high^ TILs were associated with better OS in patients with either consistent or inconsistent expression (*P *=* *0.042 & 0.026, respectively), and just as seen in the results in patients with metastatic lymph nodes, there was no prognostic value of PD‐L1 expression in OS (*P *\>* *0.05) (Fig. [5](#cam41243-fig-0005){ref-type="fig"}).

![**(A) Bar chart showing the quantity of cases of consistent/inconsistent expression of PD‐L1/CD8^+^ TILs between PLs and LNs; (B) Kaplan--Meier survival curves of patients with LN^+^ (A--C), consistent expression of PD‐L1 (between PLs and LNs) (D--F), inconsistent expression of PD‐L1 (G--I), consistent expression of CD8^+^ TILs density (J--L), inconsistent expression of CD8^+^ TILs density (M--O).** Other than patients with inconsistent expression of PD‐L1, CD8^high^ TILs was associated with better OS than CD8^low^ in the rest four groups. It showed no correlation between PD‐L1 expression and OS among all the five groups. Notes: LN^+^ refers to metastatic lymph nodes (patients staged as p‐TxN1‐3Mx). PLs, primary lesions; LNs, lymph nodes.](CAM4-7-32-g005){#cam41243-fig-0005}

Discussion {#cam41243-sec-0013}
==========

Blockade of the PD‐1/PD‐L1 pathway has been the standard second‐line therapy for advanced NSCLC [7](#cam41243-bib-0007){ref-type="ref"}, [8](#cam41243-bib-0008){ref-type="ref"}, [10](#cam41243-bib-0010){ref-type="ref"}. For patients with PD‐L1 positive expression, PD‐1/PD‐L1 inhibitors showed significantly longer PFS and OS than traditional chemotherapy in the first‐line treatment setting [25](#cam41243-bib-0025){ref-type="ref"}. However, the prevalence and prognostic value of PD‐L1 expression levels in advanced NSCLC remains controversial, so does that of CD8^+^ TILs [26](#cam41243-bib-0026){ref-type="ref"}, [27](#cam41243-bib-0027){ref-type="ref"}, [28](#cam41243-bib-0028){ref-type="ref"}, [29](#cam41243-bib-0029){ref-type="ref"}, [30](#cam41243-bib-0030){ref-type="ref"}, [31](#cam41243-bib-0031){ref-type="ref"}, [32](#cam41243-bib-0032){ref-type="ref"}, [33](#cam41243-bib-0033){ref-type="ref"}. In this study, we found PD‐L1^+^ was associated with male, smokers, SqCC and *EGFR* ^−^. CD8^+^ TILs was more common in smokers, SqCC, p‐stage I and *EGFR* ^−^. CD8^+^ TILs, not PD‐L1, was an independent predictive factor for OS.

PD‐L1^+^ was detected in 39.9% patients in our study. Of them, 59.2% (42/71) were strong positive (PD‐L1^high^). PD‐L1^high^ was also associated with SqCC and *EGFR* ^−^ (*P *=* *0.001 & 0.045). The reported extents of PD‐L1 positive expression in NSCLC ranged from 7.4% to 72.7%, which could be explained by the differences in the choice of primary IHC antibody, ethnicity, cut‐off value of positivity, and histologic types [15](#cam41243-bib-0015){ref-type="ref"}, [26](#cam41243-bib-0026){ref-type="ref"}, [27](#cam41243-bib-0027){ref-type="ref"}, [28](#cam41243-bib-0028){ref-type="ref"}, [29](#cam41243-bib-0029){ref-type="ref"}, [31](#cam41243-bib-0031){ref-type="ref"}, [32](#cam41243-bib-0032){ref-type="ref"}, [34](#cam41243-bib-0034){ref-type="ref"}, [35](#cam41243-bib-0035){ref-type="ref"}. Similarly, these studies could not reach an agreement on the clinicopathological features of PD‐L1 expression in NSCLC. A meta‐analysis including 1550 NSCLC patients showed that only poor tumor differentiation was significantly associated with PD‐L1 expression, while smoking history was marginally associated with PD‐L1 expression [36](#cam41243-bib-0036){ref-type="ref"}. However, there was no large‐scale study on PD‐L1 expression in NSCLC to validate this conclusion. As we know, resected NSCLC specimens could reflect PD‐L1 and TILs expression levels better than biopsy or tissue microarray [37](#cam41243-bib-0037){ref-type="ref"}. Our study, including 178 patients with resected NSCLC, found that PD‐L1^+^ was common in male, smokers, SqCC, and *EGFR* ^−^. Of note, there was a significant linear correlation between male, smokers, SqCC and *EGFR* ^−^ in our study. Therefore, PD‐L1^+^ may be actually associated with one of mentioned‐above parameters.

Our study found CD8^high^ TILs occurred in 41.6% patients and was associated with smokers, SqCC, p‐stage I, and *EGFR* ^−^. The similar clinicopathological features of CD8^high^ TILs with those of PD‐L1^+^ may be explained by the positive correlation between CD8^+^ TILs density and PD‐L1 expression levels [30](#cam41243-bib-0030){ref-type="ref"}, [31](#cam41243-bib-0031){ref-type="ref"}. In addition, we found CD8^high^ TILs, instead of PD‐L1^+^, was significantly associated with longer OS. CD8^+^ TILs, which form the pivotal component of the cellular immune system, constitutes the effector arm of adaptive immunity against tumor cells. More recent studies found CD8^+^ TILs was associated with better survival in NSCLC although the correlation remains controversial [13](#cam41243-bib-0013){ref-type="ref"}, [16](#cam41243-bib-0016){ref-type="ref"}, [38](#cam41243-bib-0038){ref-type="ref"}. A study included 1290 NSCLC patients showed a significant correlation between CD8^+^ TILs and longer OS only in SqCC, particularly in early stage [39](#cam41243-bib-0039){ref-type="ref"}. A recent study also suggested low CD8^+^ TILs were associated with poor survival in non‐ADC [40](#cam41243-bib-0040){ref-type="ref"}. Interestingly, we observed a significant correlation between CD8^high^ TILs and longer OS in all NSCLCs except non‐solid ADCs. On the contrary, there was a significant correlation between PD‐L1^+^ and longer OS in non‐solid ADCs and SqCCs. These findings could be explained in part by the possible impact of histological types on the correlation between CD8^+^ TILs/PD‐L1 expression and OS.

We explored the prognostic effects of PD‐L1 combined with CD8^+^ TILs because CD8^+^ TILs could produce IFN‐*γ* and induce PD‐L1 expression in different solid tumors. In all NSCLCs, the longest OS was achieved in PD‐L1^+^/CD8^high^ group while the shortest OS was in PD‐L1^+^/CD8^low^. Tokito et al. found that the PD‐L1^−^/CD8^low^ group had the shortest survival but the PD‐L1^−^/CD8^high^ group had the longest survival in locally advanced NSCLC patients receiving concurrent chemoradiotherapy [13](#cam41243-bib-0013){ref-type="ref"}. This discrepancy may be attributed to the differences in stages of disease, specimen types and cut‐off values. PD‐L1 combined with CD8^+^ TILs may be more useful to predict the prognosis of NSCLC and the efficacy of immunotherapy.

PD‐L1^+^ was associated with *EGFR* ^−^, but not with other oncogenic alternations mentioned in our study. We also observed that PD‐L1^+^ was associated with male, smokers, and SqCC. As we know, *EGFR* ^−^ was common in male patients with smoking history and SqCC histology. Moreover, CD8^+^ was also only associated with *EGFR* ^−^. It may be attributed in part to the significant correlation between PD‐L1^+^ and CD8^high^ TILs in our study. The number of studies evaluating the correlation of PD‐L1/CD8^+^ TILs with ODM was limited. Some studies reported a significant association between PD‐L1 expression with *EGFR* ^+^ or *KRAS* ^+^ in NSCLCs, but others did not [26](#cam41243-bib-0026){ref-type="ref"}, [35](#cam41243-bib-0035){ref-type="ref"}, [41](#cam41243-bib-0041){ref-type="ref"}, [42](#cam41243-bib-0042){ref-type="ref"}. Several clinical trials reported PD‐L1 expression was associated with *EGFR* ^+^ and *ALK* ^+^ in NSCLC with up to 72% and 78% of PD‐L1 positive rates in *EGFR* ^+^ and *ALK* ^+^ patients, respectively [31](#cam41243-bib-0031){ref-type="ref"}, [35](#cam41243-bib-0035){ref-type="ref"}, [41](#cam41243-bib-0041){ref-type="ref"}, [43](#cam41243-bib-0043){ref-type="ref"}. However, the association between PD‐L1 expression and these ODMs was not observed in other studies [44](#cam41243-bib-0044){ref-type="ref"}. The PD‐L1 expression levels on tumor cells may be up‐ or down‐regulated by variable antitumor treatments. Therefore, resected NSCLC specimens from patients in early stages may reflect the initial correlation between PD‐L1 expression and ODMs.

The last but not the least, our study showed inconsistent PD‐L1 expression levels between primary lesions and metastatic lymph nodes occurred in 23 of 58 (39.7%) patients. Moreover, there was a significant correlation between CD8^+^ TILs and longer OS in patients with consistent PD‐L1 expressions between primary lesions and metastatic lymph nodes but not in patients with inconsistent PD‐L1 expression. The question is which specimens should we use to detect PD‐L1 expression in advanced NSCLC. The primary lesions or the metastatic lymph nodes? We considered that it may be better to evaluate PD‐L1 expression in both for advanced NSCLC patients. Patients with consistent positive PD‐L1 expressions may obtain better survival benefit from anti‐PD‐1 inhibitors.

Although many studies and clinical series reported the prevalence, clinicopathological and/or molecular features, and prognostic value of PD‐L1 expression in NSCLC, there were conflicting results on these aspects. The above‐described discrepant results could be explained by the differences in ethnicity, specimen types, PD‐L1 IHC protocols (including primary antibodies), scoring criteria, cut‐off values, targeted cell types (tumor cells or TILs), and locations (membranous or cytoplasmic). The absence of a universally accepted PD‐L1 IHC standard and its interpretation make it extremely difficult to determine the prognostic or predictive value of PD‐L1 expression in NSCLC. Besides, the significance of PD‐L1 expression from a single‐biopsy specimen in advanced NSCLC may be overestimated in clinical practice. Therefore, a large‐scale, prospective study is warranted to determine the prevalence and role of PD‐L1 expression, comparison on PD‐L1 expression between single‐biopsies and resected specimens, and the correlation with TILs in NSCLC population.
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**Figure S1.** Representative IHC images for PD‐L1 and CD8^+^ TILs in NSCLC.
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**Figure S2.** Representative images of positive and negative controls for PD‐L1 IHC staining.
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Click here for additional data file.
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